A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)

Trial Profile

A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs SL 701 (Primary) ; Bevacizumab; Poly ICLC
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Stemline Therapeutics
  • Most Recent Events

    • 16 Nov 2017 According to a Stemline Therapeutics media release, results from this trial were presented at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO).
    • 03 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
    • 03 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top